Can a rheumatoid arthritis drug save lung transplants?

NCT ID NCT06033196

Recruiting now Disease control Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study tests whether adding tocilizumab to standard anti-rejection drugs can prevent chronic lung allograft dysfunction (CLAD) in 350 lung transplant recipients. Participants receive either tocilizumab or a placebo for 20 weeks, and researchers track CLAD, re-transplant listing, or death over 36 months. The goal is to see if tocilizumab improves long-term transplant success.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tocilizumab (also known as Actemra)
What this could lead to: If it works, this could reduce the risk of chronic lung rejection and improve survival after lung transplant.
What could go wrong: This is a phase 2 trial, so results are still uncertain. Tocilizumab may cause side effects like infections, and the benefit over standard care is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG TRANSPLANT

Contacts and locations

Locations

Barnes Jewish Hospital/ Washington University SOM (Site #: 71191)
RECRUITING

St Louis, Missouri, 63110, United States
Boston Children's Hospital and Harvard Medical School (Site #: 71001)
WITHDRAWN

Boston, Massachusetts, 02215, United States
Cedars Sinai Medical Center (Site #: 71146)
RECRUITING

Beverly Hills, California, 90211, United States
Cleveland Clinic (Site #: 71101)
RECRUITING

Cleveland, Ohio, 44195, United States
Columbia University Medical Center (Site #: 71113)
RECRUITING

New York, New York, 10032, United States
David Geffen School of Medicine at UCLA (Site #: 71123)
RECRUITING

Los Angeles, California, 90095, United States
Duke University Medical Center (Site #: 71139)
RECRUITING

Durham, North Carolina, 27710, United States
Emory University (Site #: 71103)
RECRUITING

Atlanta, Georgia, 55905, United States
Houston Methodist Hospital (Site #: 71120)
WITHDRAWN

Houston, Texas, 77030, United States
Massachusetts General Hospital (Site #: 71107)
RECRUITING

Boston, Massachusetts, 02114, United States
Mayo Clinic Rochester (Site #: 71160)
NOT_YET_RECRUITING

Rochester, Minnesota, 55905, United States
Ohio State University Medical Center (Site #: 71196)
RECRUITING

Columbus, Ohio, 43210, United States
St. Joseph's Hospital and Medical Center (Site #: 71192)
RECRUITING

Phoenix, Arizona, 85013, United States
St. Louis Children's Hospital of Washington University (Site #: 71006)
WITHDRAWN

St Louis, Missouri, 63110, United States
Temple University (Site #: 71197)
NOT_YET_RECRUITING

Philadelphia, Pennsylvania, 19140, United States
University of Florida Shands Hospital (Site #: 71131)
NOT_YET_RECRUITING

Gainesville, Florida, 32610, United States
University of Maryland Medical Center (Site #: 71138)
WITHDRAWN

Baltimore, Maryland, 21201, United States
University of Texas Health Science at San Antonio (Site #: 71198)
NOT_YET_RECRUITING

San Antonio, Texas, 78229, United States
University of Texas Southwestern (Site #: 71187)
RECRUITING

Dallas, Texas, 75390, United States
University of Utah Medical Center (Site #: 71126)
RECRUITING

Salt Lake City, Utah, 84132, United States
Vanderbilt University (Site #: 71174)
RECRUITING

Nashville, Tennessee, 37232-0393, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.